STAT+: After 10 years of game-changing immunotherapies, a cancer conference celebrates — and sees more work to do
BARCELONA, Spain — Ten years ago, a new type of cancer treatment reached the market….
Category: Merck
A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids
What’s next for Akeso and Summit Therapeutics after their cancer immunotherapy outperformed Merck’s Keytruda in…
STAT+: Detailed data show Summit therapy beat Merck blockbuster Keytruda in late-stage lung cancer trial
SAN DIEGO — For years, Merck’s drug Keytruda has dominated cancer immunotherapy, racking up dozens…
Merck Ebola vaccine Ervebo shown to offer substantial protection
Merck’s Ebola vaccine offered substantial protection to people vaccinated during the 2018-2020 outbreak in the…
STAT+: Merck shares fall as sales of HPV vaccine drop in China
Shares of Merck fell 9% Tuesday after the company reported that in the second quarter,…
New Merck pneumococcal vaccine wins FDA approval
The Food and Drug Administration on Monday approved Merck’s new pneumococcal vaccine for adults 18…
STAT+: Analysis of pharmaceutical R&D ranks Novo Nordisk and Johnson & Johnson above their peers
When it comes to bringing an experimental drug to market and selling it, Novo Nordisk,…
STAT+: During the pandemic, were great vaccines bad business? A company-by-company review
It’s been four years since Covid-19 emerged, igniting a pandemic that killed millions of people…
Ebola vaccine cuts fatality even in people who were infected before the jab, new study shows
A new study has shown that people vaccinated against Ebola who still developed the disease…
In a showy hearing, Bernie Sanders gets few answers about lower drug prices
WASHINGTON — Call it Sen. Bernie Sanders’ prescription drug pricing theater. The hearing, featuring Merck…
STAT+: Merck, Johnson & Johnson CEOs agree to testify in Congress on high drug prices, avoiding Bernie Sanders’ subpoena
WASHINGTON — Merck CEO Robert Davis and Johnson and Johnson CEO Joaquin Duato have agreed…
STAT+: Bernie Sanders proposes subpoenas of CEOs of J&J, Merck on drug prices
WASHINGTON — Senate health committee chair Bernie Sanders has taken a step toward subpoenaing the…
KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Demonstrated Clinically Meaningful Tumor Response Rates in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma
Dateline City: KENILWORTH, N.J. & WOODCLIFF LAKE, N.J. Analyses from KEYTRUDA Plus LENVIMA Trials to…
Merck’s KEYTRUDA® (pembrolizumab) Superior to Standard of Care Chemotherapy in Patients with MSI-H Colorectal Cancer
Dateline City: KENILWORTH, N.J. KEYTRUDA Monotherapy Significantly Reduced Risk of Disease Progression or Death by…
Merck Announces Third-Quarter 2020 Dividend
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Merck and Ridgeback Bio Collaborate to Advance Development of Novel Antiviral Candidate, EIDD-2801
Dateline City: KENILWORTH, N.J. & MIAMI Clinical Studies of EIDD-2801 for the Treatment of Patients…
IAVI and Merck Collaborate to Develop Vaccine Against SARS-CoV-2
Dateline City: KENILWORTH, N.J. & NEW YORK New Collaboration to Leverage Complementary Expertise and Capabilities…
Merck to Acquire Themis
Dateline City: KENILWORTH, N.J. Merck to Apply its Industry-Leading Vaccine Development Capabilities to SARS-CoV-2 Vaccine…
Merck to Announce Multiple Scientific Efforts to Combat COVID-19
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
LYNPARZA® (olaparib) Approved by FDA for Treatment of HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer That Has Progressed Following Prior Treatment with Enzalutamide or Abiraterone
Dateline City: KENILWORTH, N.J. Only PARP Inhibitor to Improve Overall Survival vs. Enzalutamide or Abiraterone…
Infectious Disease Connect and ILÚM Health Solutions Combine to Advance Precision Treatment of Infectious Diseases and Antimicrobial Stewardship
Dateline City: KENILWORTH, N.J. & PITTSBURGH Agreement Includes Strategic Investments from UPMC Enterprises and Merck…
Merck Announces Appointment of Organon & Co. Chief Financial Officer and Chief Information Officer
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Merck to Present at the UBS Virtual Global Healthcare Conference
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
New Combination Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Clinical Benefit in Stage III Non-Small Cell Lung Cancer (NSCLC) and Reinforce Long-Term Survival in Metastatic NSCLC
Dateline City: KENILWORTH, N.J. First Combination Data in Stage III NSCLC from KEYNOTE-799 Showed KEYTRUDA…
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Chemotherapy in Certain Patients with Metastatic Triple-Negative Breast Cancer
Dateline City: KENILWORTH, N.J. Data from Pivotal Phase 3 Trial Showed KEYTRUDA Plus Chemotherapy Reduced…
Merck’s KEYTRUDA® (pembrolizumab) Superior to Brentuximab Vedotin (BV), a Standard of Care, in Patients With Classical Hodgkin Lymphoma (cHL) in Head-to-Head Phase 3 Trial
Dateline City: KENILWORTH, N.J. KEYNOTE-204 is the First Positive Phase 3 Trial of an Anti-PD-1…
Merck’s Novel HIF-2α Inhibitor Showed an Objective Response Rate of Nearly 30% in Patients with von Hippel-Lindau (VHL) Disease-Associated Clear Cell Renal Cell Carcinoma
Dateline City: KENILWORTH, N.J. First-Time Data for MK-6482 Reinforce Innovative Science in Merck’s Expansive and…
Merck Animal Health to Acquire U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals
Dateline City: MADISON, N.J. Further Solidifies Merck Animal Health’s Position in the U.S. Companion Animal…
LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer
Dateline City: KENILWORTH, N.J. Improved the Median Time to Disease Progression (37.2 months) vs. Bevacizumab…
Merck Announces Virtual 2020 Annual Shareholders Meeting
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States…
Merck to Present at the BofA Securities 2020 Health Care Conference
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Merck to Present New Data from its Broad Oncology Portfolio and Pipeline at the ASCO20 Virtual Scientific Program
Dateline City: KENILWORTH, N.J. ASCO Plenary Session to Feature Phase 3 Data for KEYTRUDA®(pembrolizumab) in…
Results of Phase 3 Trial Evaluating the Efficacy and Safety of Merck’s RECARBRIO™ (Imipenem, Cilastatin, and Relebactam) Versus Piperacillin and Tazobactam in Adult Patients with HABP/VABP Now Available
Dateline City: KENILWORTH, N.J. U.S. Food and Drug Administration (FDA) Accepted for Review a Supplemental…
Merck Commits Additional $10 Million to COVID-19 Relief Efforts to Help Disparately Impacted Patients and Communities
Dateline City: KENILWORTH, N.J. Merck is Proud to Make New Commitment in Support of #GivingTuesdayNow…
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Use at an Additional Recommended Dose of 400 mg Every Six Weeks for All Approved Adult Indications
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Merck Announces First-Quarter 2020 Financial Results
Dateline City: KENILWORTH, N.J. First-Quarter 2020 Worldwide Sales Were $12.1 Billion, an Increase of 11%;…
First Clinical Outcomes Evaluating Six-Week Dosing Schedule for Merck’s KEYTRUDA® (pembrolizumab) Presented at AACR Virtual Annual Meeting I
Dateline City: KENILWORTH, N.J. Data Demonstrate Efficacy and Safety of KEYTRUDA 400 mg Every Six…
Merck and Institute for Systems Biology Collaborate to Define Molecular Mechanisms of SARS-CoV-2 Infection and Identify Potential Prognostic Biomarkers
Dateline City: KENILWORTH, N.J. & SEATTLE KENILWORTH, N.J. & SEATTLE–(BUSINESS WIRE)–Merck (NYSE: MRK), known as…
LYNPARZA® (olaparib) Demonstrated Overall Survival Benefit in Phase 3 PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
Dateline City: KENILWORTH, N.J. Only PARP Inhibitor to Improve Overall Survival vs. New Hormonal Agent…
Merck Resubmits Supplemental Biologics License Applications (sBLAs) for KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule
Dateline City: KENILWORTH, N.J. Additional sBLAs Filed Across All Approved Adult Indications KENILWORTH, N.J.–(BUSINESS WIRE)–Merck…
Merck Broadens Patient Support and Assistance Programs as Part of Overall COVID-19 Relief Efforts
Dateline City: KENILWORTH, N.J. Support is Available for Eligible U.S. Patients Who Have Lost Their…
Merck Announces US Launch of ONTRUZANT® (trastuzumab-dttb), a Biosimilar of Herceptin® (trastuzumab)
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
.jpg)
KOSELUGO® (selumetinib) Approved by FDA for Pediatric Patients Two Years and Older With Neurofibromatosis Type 1 and Symptomatic, Inoperable Plexiform Neurofibromas
Dateline City: KENILWORTH, N.J. First Medicine Approved to Treat This Rare and Debilitating Condition KENILWORTH,…
Merck Announces $3M Commitment to Address Critical Maternal Health Needs During COVID-19 Pandemic
Dateline City: KENILWORTH, N.J. New Merck for Mothers Commitment Adds to Merck’s Overall Support to…
Merck Receives Priority Review from FDA for Second Application for KEYTRUDA® (pembrolizumab) Based on Biomarker, Regardless of Tumor Type
Dateline City: KENILWORTH, N.J. Supplemental Biologics License Application (sBLA) Accepted for KEYTRUDA Monotherapy in Patients…
Merck Announces KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival as First-Line Treatment for Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer
Dateline City: KENILWORTH, N.J. First Positive Head-to-Head Phase 3 Trial Comparing a Single-Agent Cancer Medicine…
Merck to Hold First-Quarter 2020 Sales and Earnings Conference Call on April 28
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic
Dateline City: KENILWORTH, N.J. & NEW YORK & INDIANAPOLIS Three leading biopharmaceutical companies have announced…
Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death, Compared to Placebo, When Given in Combination with Available Heart Failure Therapies
Dateline City: KENILWORTH, N.J. Phase 3 VICTORIA Trial is the First Contemporary Outcomes Study Focused…
Merck to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response
Dateline City: KENILWORTH, N.J. Merck is Contributing 300,000 Masks to New Jersey’s Office of Homeland…